Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups : Episode 5

Elacestrant: Clinical Pearls for AE Management

November 25, 2024

By Rahul Gosain, MD
Rohit Gosain, MD

Opinion

Video

Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring and management of adverse reactions effects (AEs) to elacestrant, emphasizing strategies to help patients remain on therapy while maximizing their quality of life.

EP: 1.Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC

EP: 2.Incidence of ESR1 mutations and best practices for testing

EP: 3.Co-occurrence of ESR1m with other alterations

EP: 4.Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease

Now Viewing

EP: 5.Elacestrant: Clinical Pearls for AE Management

EP: 6.EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease

EP: 7.Emerging Data on Oral SERDS

What has been learned about proactive monitoring and management for adverse reactions to elacestrant that can help keep patients on therapy and maximize their quality of life?

Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.